NCT06781359 Study on Plasmablastic Lymphoma Patients
| NCT ID | NCT06781359 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Condition | Plasmablastic Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-02-14 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-02-14 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022 * Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report * Age \> 18 years old * Availability of complete medical records * Availability of histopathological material requested by the study Exclusion Criteria: * Any other histology than PBL * Lack of complete medical records * Lack of histopathological material requested by the study
Contact & Investigator
Alessia Castellino, MD
PRINCIPAL INVESTIGATOR
UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy
Frequently Asked Questions
Who can join the NCT06781359 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Plasmablastic Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06781359 currently recruiting?
Yes, NCT06781359 is actively recruiting participants. Contact the research team at startup@filinf.it for enrollment information.
Where is the NCT06781359 trial being conducted?
This trial is being conducted at Aviano, Italy, Ascoli Piceno, Italy, Brescia, Italy, Cuneo, Italy and 11 additional locations.
Who is sponsoring the NCT06781359 clinical trial?
NCT06781359 is sponsored by Fondazione Italiana Linfomi - ETS. The principal investigator is Alessia Castellino, MD at UO Ematologia, AO Santa Croce e Carle, Cuneo - Italy. The trial plans to enroll 200 participants.